title: A clinical study on the significance of platelet-activating factor in the pathophysiology of septic disseminated intravascular coagulation in surgery.
abstract: BACKGROUND
  To investigate the characteristic differences between disseminated intravascular coagulation (DIC) found in surgical sepsis (septic DIC) and those found in patients with advanced gastrointestinal cancer (cancer DIC), we focused on two substances, endotoxin and platelet- activating factor (PAF).
  
  
  METHODS
  Coagulation test values were determined in 36 patients with DIC, and endotoxin and PAF concentrations in 13 of these patients. Seven septic patients were given a PAF antagonist to evaluate its usefulness in treating thrombocytopenia.
  
  
  RESULTS
  Blood PAF and endotoxin concentrations were higher in patients with septic DIC, but they were almost normal in those with cancer DIC. Blood PAF concentrations showed a strong positive relationship to endotoxin only in septic DIC. There was a negative correlation between PAF concentrations and platelet counts in septic patients; platelet counts gradually increased after the administration of a PAF antagonist.
  
  
  CONCLUSIONS
  PAF is inversely associated with platelet counts in patients with septic DIC. A PAF antagonist showed marked inhibitory effects on the characteristic changes of septic DIC, especially thrombocytopenia.
authors.affiliation: First Department of Surgery, National Defense Medical College, Namiki, Saitama, Japan.
authors.forename: S
authors.initials: S
authors.lastname: Ono
authors.forename: H
authors.initials: H
authors.lastname: Mochizuki
authors.forename: S
authors.initials: S
authors.lastname: Tamakuma
mesh_terms: D006528:Carcinoma, Hepatocellular / Q000150:complications; D003627:Data Interpretation, Statistical; D004211:Disseminated Intravascular Coagulation / Q000097:blood / Q000209:etiology / Q000503:physiopathology*; D004731:Endotoxins / Q000097:blood; D005770:Gastrointestinal Neoplasms / Q000150:complications; D006801:Humans; D008113:Liver Neoplasms / Q000150:complications; D010880:Piperidines / Q000627:therapeutic use*; D010972:Platelet Activating Factor / Q000037:antagonists & inhibitors* / Q000502:physiology*; D011726:Pyridinium Compounds / Q000627:therapeutic use*; D018805:Sepsis / Q000097:blood / Q000188:drug therapy / Q000503:physiopathology*; D013514:Surgical Procedures, Operative
chemical_list: D004731:Endotoxins; D010880:Piperidines; D010972:Platelet Activating Factor; D011726:Pyridinium Compounds; C072429:E 5880